Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MKC-1 · 6 trials · 9 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Ovarian Cancer Patients |
| B | EXPERIMENTAL | Endometrial Cancer Patients |
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MKC-1 | DRUG | capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles |
| pemetrexed | DRUG | standard dosing of 500 mg/m2 infused every 21 days |
Inclusion Criteria: 1. Provide written informed consent (and HIPAA authorization for release of protected health information, as applicable) prior to any study related assessments. 2. Histologically confirmed epithelial ovarian cancer, primary peritoneal carcinomatosis, fallopian tube cancers, or e...
Top 20 of 87 competitors
MKC-1 is an investigational small molecule being studied for the treatment of advanced cancer, pancreatic cancer, ovarian cancer, hematological malignancies, and breast cancer. It has been evaluated in clinical trials for these oncology indications, though it remains in clinical development and is not approved.
MKC-1 is being developed by CASI Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol CASI. The company has sponsored clinical trials of MKC-1 in oncology indications.
MKC-1 has completed Phase 1 and Phase 2 clinical trials. It is an investigational drug that has not received FDA approval. The completed trials include Phase 1 studies in advanced cancer and hematological malignancies, and Phase 2 studies in pancreatic and ovarian cancer.
MKC-1 has been studied in four completed clinical trials. These include NCT00408226, a Phase 1 study of MKC-1 with pemetrexed in advanced cancer; NCT00506402, a Phase 1 study in hematologic malignancies; NCT00568646, a Phase 2 study in pancreatic cancer; and NCT00607607, a Phase 2 study in ovarian or endometrial cancer.
MKC-1 is not known to have alternative names. It is identified by the code name MKC-1 in clinical trials and is being developed by CASI Pharmaceuticals.